Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · MYRIAD GENETICS INC (MYGN)

Myriad Genetics Q3 revenue falls 1% to $202.7 million; raises revenue guidance midpoint

Mixed Impact 4 of 5 guidance Written later

Myriad Genetics reported third-quarter 2026 revenue of $202.7 million, down 1% from a year earlier, with a net loss of $43.9 million, or $0.46 per share. The company raised the midpoint of its full-year 2026 revenue guidance to $780 million to $790 million and agreed on October 19, 2026 to sell its Prenatal Health business to Labcorp for $210 million in cash plus inventory.

Key points

  • Q3 2026 revenue $202.7 million, down from $205.7 million; Cancer Care Continuum and Mental Health volume up 3%, Prenatal Health volume down 11%
  • Q3 2026 operating loss $39.9 million; net loss $43.9 million, or $0.46 per share, versus $27.4 million a year earlier
  • Full-year 2026 revenue guidance $780 million to $790 million; Prenatal Health sale to Labcorp for $210 million in cash expected to close by early 2027

The filing

CompanyMYRIAD GENETICS INC (MYGN)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:07 PM ET
Accession number0001628280-26-070135

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.